IP Library Granted Patent US 8,916,556
Granted Patent B2
US 8,916,556 · App. 12/762,947 · Granted Dec 23, 2014

Pharmaceutical formulations comprising neurotrophin mimetics

Inventors: Frank M. Longo (Menlo Park, CA); Stephen M. Massa (Burlingame, CA)
Assignees: The University of North Carolina at Chapel Hill; The Regents of The University of California; The United States of America represented by the Department of Vetran Affairs
C07K16/2878A61K31/497A61K31/522A61K31/537A61K31/496C07K2316/96A61K31/155A61K31/445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,556
App. No.
12/762,947
Granted
Dec 23, 2014
Kind
B2
Abstract

Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75 NTR receptor molecule. Enhanced survival of neural and other cells has been observed.

Claims (12)

1. A pharmaceutical formulation comprising a unit dose of an active ingredient and a pharmaceutical grade carrier, wherein said active ingredient is selected from the group consisting of a compound having the structure:

wherein:

m is an integer from 1 to 8;

R 3 is selected from the group consisting of H, alkyl, cycloalkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; and

R 5 and R 6 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl;

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical formulation comprising a unit dose of an active ingredient and a pharmaceutical grade carrier, wherein said active ingredient is a compound having the structure:

or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical formulation of claim 1 , wherein said formulation is a liquid solution, suspension, emulsion, tablet, pill, or capsule.

4. The pharmaceutical formulation of claim 3 , formulated for administration to a human.

5. The pharmaceutical formulation of claim 2 , wherein said formulation is a liquid solution, suspension, emulsion, tablet, pill, or capsule.

6. The pharmaceutical formulation of claim 5 , formulated for administration to a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2017
From: LONGO, FRANK M.
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 041250/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2017
From: MASSA, STEPHEN M.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 041254/0718 →
CONFIRMATORY LICENSE Recorded Sep 29, 2014
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033845/0668 →
Continuity (3)
Continuation 11396936 · Apr 3, 2006
Provisional Application 60671785 · Apr 15, 2005
Related Publication 20100267727A1 · Oct 21, 2010